Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 4Myeloid 2Thoracic 1Plasma cell 1Genitourinary 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 160Leukemia, Myeloid, Acute 123Leukemia, Myelomonocytic, Chronic 65Leukemia 35Myeloproliferative Disorders 23Primary Myelofibrosis 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Anemia, Refractory, with Excess of Blasts 11Hematologic Neoplasms 10Myelodysplastic-Myeloproliferative Diseases 9Recurrence 8Multiple Myeloma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 7Lymphoma, Non-Hodgkin 6Leukemia, Biphenotypic, Acute 6Lymphoma 5Polycythemia Vera 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myelomonocytic, Acute 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Erythroblastic, Acute 4Hematologic Diseases 4Anemia, Refractory 4Thrombocythemia, Essential 3Prostatic Neoplasms 3Neoplasm, Residual 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3

Interventions

Cyclophosphamide 72fludarabine phosphate 69Peripheral Blood Stem Cell Transplantation 58Mycophenolic Acid 56Whole-Body Irradiation 44Tacrolimus 44Cyclosporine 43Antilymphocyte Serum 39Busulfan 37Filgrastim 28Radiotherapy 27Methotrexate 26Cord Blood Stem Cell Transplantation 24Melphalan 20Methylprednisolone 19fludarabine 13Flow Cytometry 11Etoposide 11Sirolimus 10Therapeutics 9Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 7Cytarabine 7Cyclosporins 7Alemtuzumab 7thymoglobulin 6sargramostim 6Polymerase Chain Reaction 6Rituximab 5Allopurinol 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Azacitidine × Myeloid × Clear all
NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Prelude Therapeutics

Phase 1 Terminated
21 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT00006019 2013-06-24

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
GenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Leukemia, Monocytic, Acute, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡